Patents by Inventor Israel Cañadas

Israel Cañadas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
    Publication number: 20240125787
    Abstract: Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Applicants: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: David Barbie, Israel Cañadas, Shunsuke Kitajima, Thanh Barbie
  • STING levels as a biomarker for cancer immunotherapy
    Patent number: 11874276
    Abstract: Provided herein are Stimulator of Interferon Genes (STING) and Stimulated 3 Prime Antisense Retroviral Coding Sequences (SPARCS) genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 16, 2024
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: David Barbie, Israel Cañadas, Shunsuke Kitajima, Thanh Barbie
  • STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
    Publication number: 20210025893
    Abstract: Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Application
    Filed: April 5, 2019
    Publication date: January 28, 2021
    Applicants: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital Inc.
    Inventors: David Barbie, Israel Cañadas, Shunsuke Kitajima, Thanh Barbie
  • HEPATOCYTE GROWTH FACTOR AS MARKER OF PROGNOSIS IN SMALL CELL LUNG CANCER (SCLC)
    Publication number: 20160327559
    Abstract: The invention relates to a new marker, the hepatocyte growth factor (HGF) in serum or plasma for the prognosis of small-cell lung cancer (SCLC). The invention also provides methods for selecting subjects suffering from SCLC that are candidate to respond to certain substances inhibiting certain kinases expressed in the tumours. There are also encompassed the use of immunoassay and nucleic acid reagents for detecting HGF in serum or plasma, said reagents for carrying out the prognostic method.
    Type: Application
    Filed: April 24, 2014
    Publication date: November 10, 2016
    Inventors: Edurne ARRIOLA APERRIBAY, Israel CAÑADAS CASTILLO, Ana ROVIRA GUERIN, Joan ALBANELL MESTRES